Barclays stock edges up after fresh buyback update — what investors watch next
15 January 2026
1 min read

Barclays stock edges up after fresh buyback update — what investors watch next

London, Jan 15, 2026, 08:29 GMT — Regular session

  • Barclays shares rose roughly 0.6% during early trading in London.
  • The bank announced a fresh tranche of share repurchases as part of its ongoing buyback program.
  • Investors are now eyeing the February results update closely, looking for any clues on capital returns.

Shares of Barclays PLC (BARC.L) nudged up on Thursday following the bank’s announcement of an additional round of share buybacks, pushing further a programme that’s supported the stock’s momentum into 2026. At 0816 GMT, the price rose 0.6% to 482.7 pence. (Investors Chronicle)

This update barely moved the day’s tape but hits on a theme investors revisit constantly: capital returns. Buybacks involve a company repurchasing and canceling its own stock, cutting the share count and potentially boosting earnings per share over time.

European stocks edged higher Thursday morning. UK November GDP came in at 0.3%, surpassing expectations for a more modest increase, which provided some support for local banks. (Reuters)

Barclays bought 3,545,144 ordinary shares on Jan. 14 at a volume-weighted average price of 479.5291 pence — factoring in the volume traded at each price level. These shares are set to be cancelled. Since the buyback programme launched on Oct. 23, 2025, the bank has repurchased a total of 75,171,359 shares. (Investegate)

The company confirmed its latest share buys took place on the London Stock Exchange via Citigroup Global Markets Limited. Following the cancellation, it will hold 13,843,359,135 ordinary shares with voting rights outstanding.

Buybacks alone won’t carry the load. Barclays’ upcoming updates on costs, credit quality, and capital will be far more crucial than daily repurchase figures. Investors are focused on how well bank earnings can hold up if growth slows or funding costs change.

There is a downside risk. A slowing economy could drive up bad loans, while rising regulatory or litigation expenses might cut into capital that would otherwise go back to shareholders, reducing funds available for buybacks.

Investors are eyeing Barclays’ full-year 2025 results, due Feb. 10, for fresh insight on profitability and the trajectory of future capital returns. (Home)

Stock Market Today

  • BridgeBio Pharma Valuation After Attruby Uptake, BBP-418 Data, and Late-Stage Pipeline Momentum
    January 15, 2026, 6:33 AM EST. BridgeBio Pharma (BBIO) has drawn fresh attention after reporting more than 6,600 prescriptions for its ATTR-CM therapy Attruby, releasing interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. Our latest analysis notes a 90-day share-price gain of 41.6% and a 3-year total shareholder return, with the stock near US$77.90. The fair value estimate stands around US$84.65, implying upside if late-stage programs convert to revenue and earnings. Analysts' consensus price target is US$63.81, with a range from US$41.00 to US$95.00. Risks include durability of Attruby, negative trial data, and regulatory delays. Valuation shows BridgeBio trading at a discount to our fair value, but a high P/S ratio (~42.4x vs 26.8x fair). A premium valuation hinges on execution and margin expansion.
SGX stock dips late in trade as tariff fog and a fresh IPO test sentiment ahead of Feb 5 results
Previous Story

SGX stock dips late in trade as tariff fog and a fresh IPO test sentiment ahead of Feb 5 results

Standard Chartered stock rises as buyback rolls on; eyes on next results
Next Story

Standard Chartered stock rises as buyback rolls on; eyes on next results

Go toTop